SCHEMBL3027860

SCHEMBL3027860

N#Cc1cc(Cl)cc(Oc2c([N+](=O)[O-])ccc(CC(=O)O)c2F)c1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.44
CYP1A2 P05177 1/20 0.39
VCAM1 P19320 3/20 0.37
MERTK Q12866 1/20 0.36
KCNH2 Q12809 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
EPAS1 Q99814 3/20 0.35
MAPT P10636 1/20 0.34
SNCA P37840 1/20 0.34
SLC22A12 Q96S37 1/20 0.33
VEGFA P15692 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4754814 1.00 CYP3A4 (0.44) CYP3A4CYP1A2VCAM1MERTKKCNH2
SCHEMBL3642514 0.89 CYP1A2 (0.39) CYP3A4CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL13661733 0.88 CYP3A4 (0.45) CYP3A4VCAM1MERTKKCNH2CYP2C9
SCHEMBL1344613 0.85 CYP3A4 (0.55) CYP3A4KCNH2CYP2C9CYP2C19EPAS1
SCHEMBL4752770 0.85 CYP1A2 (0.41) CYP1A2EPAS1MAPTVEGFANPC1
SCHEMBL3038920 0.85 CYP1A2 (0.41) CYP1A2EPAS1MAPTVEGFANPC1
SCHEMBL3016476 0.84 VCAM1 (0.44) CYP3A4VCAM1MERTKKCNH2EPAS1
SCHEMBL1344803 0.83 CYP3A4 (0.47) CYP3A4KCNH2CYP2C9CYP2C19EPAS1
SCHEMBL4752470 0.83 CYP3A4 (0.49) CYP3A4KCNH2CYP2C9CYP2C19EPAS1
SCHEMBL16175755 0.83 CYP3A4 (0.61) CYP3A4KCNH2CYP2C9CYP2C19EPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP disclosed
WO-2008157273-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed
WO-2008157330-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 CYP3A4 169/4885CYP1A2 301/4885VCAM1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.